Lonza Signs Applied Protein Services Agreement with ImmuneMed for Immunogenicity Risk Assessment and Deimmunization of Novel Protein
13-Dec-2011 -
Lonza announced an agreement with ImmuneMed, Inc. for the in silico screening followed by deimmunization of their Virus Suppressing Factor (VSF), under investigation for the treatment of viruses such as the encephalomyocarditus, influenza and hepatitis. Under the agreement, Lonza will perform an ...
deimmunization
hepatitis
influenza
+1